CMG Pharmaceutical Co., Ltd.

KOSDAQ:A058820 Stock Report

Market Cap: ₩265.0b

CMG Pharmaceutical Valuation

Is A058820 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A058820 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate A058820's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A058820's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A058820?

Key metric: As A058820 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for A058820. This is calculated by dividing A058820's market cap by their current earnings.
What is A058820's PE Ratio?
PE Ratio91.7x
Earnings₩2.89b
Market Cap₩265.01b

Price to Earnings Ratio vs Peers

How does A058820's PE Ratio compare to its peers?

The above table shows the PE ratio for A058820 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average14.1x
A041960 Komipharm International
24.2xn/a₩275.4b
A001630 Chong Kun Dang Holdings
5.1x-62.7%₩244.2b
A243070 Huons
7.4x15.3%₩299.8b
A003220 Daewon Pharmaceutical
19.7x45.6%₩312.7b
A058820 CMG Pharmaceutical
91.7xn/a₩265.0b

Price-To-Earnings vs Peers: A058820 is expensive based on its Price-To-Earnings Ratio (91.7x) compared to the peer average (14.1x).

Price to Earnings Ratio vs Industry

How does A058820's PE Ratio compare vs other companies in the KR Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
A007370 Jin Yang Pharmaceutical
2.4xn/aUS$47.71m
No more companies available in this PE range
A058820 91.7xIndustry Avg. 12.7xNo. of Companies9PE01020304050+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: A058820 is expensive based on its Price-To-Earnings Ratio (91.7x) compared to the KR Pharmaceuticals industry average (12.7x).

Price to Earnings Ratio vs Fair Ratio

What is A058820's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A058820 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio91.7x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate A058820's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Hugel

₩3.0t

Develops and manufactures biopharmaceuticals in South Korea and internationally.

A145020

₩265,000.00

7D

-1.3%

1Y

69.8%

Medy-Tox

₩867.0b

Operates as a biopharmaceutical company in South Korea.

A086900

₩129,100.00

7D

4.7%

1Y

-41.2%

J2KBIO

₩52.5b

A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.

A420570

₩9,650.00

7D

1.7%

1Y

n/a